Apyx Medical Corp. Hits New 52-Week High of $5.08, Up 203.75%

Apyx Medical Corp., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 5.08 on June 9, 2026. This achievement marks a remarkable 203.75% increase in the stock's performance over the past year, significantly outpacing the S&P 500's growth of 22.99% during the same period. With a market capitalization of USD 152 million, Apyx Medical Corp. operates in a competitive industry characterized by innovation and rapid advancements. The company's financial metrics reveal a debt-to-equity ratio of 0.24, indicating a relatively low level of debt compared to equity. However, the return on equity stands at -76.38%, reflecting challenges in profitability. Despite not offering dividends, Apyx Medical's price-to-book ratio of 10.47 suggests that investors are valuing the company at a premium relative to its book value. The stock's previous 52-week low was recorded at USD 1.59, highlighting the significant upward movement in its price. This milestone underscores Apyx Medical Corp.'s evolving position within the biotechnology landscape.